Genesis Therapeutics
Genesis Therapeutics, a biotech company, leverages AI-powered drug discovery to accelerate the development of new medicines and has secured a $200M Series B funding.
Company History
Genesis Therapeutics has rapidly emerged as a significant player in the biotechnology sector by leveraging advanced AI technologies for drug discovery. The company recently closed an oversubscribed $200M Series B funding round, underscoring strong investor confidence. Genesis Therapeutics aims to revolutionize the field of drug discovery and development by implementing pioneering approaches to AI, such as 3D spatial graph modeling and molecular simulation.
AI-Powered Drug Discovery
Genesis Therapeutics utilizes AI-powered drug discovery to identify novel protein targets, explore unexplored chemical spaces, and accelerate the development of new medications. Their approach integrates 3D spatial graph modeling and advanced molecular simulations, aiming to produce novel drug candidates. By using these cutting-edge technologies, Genesis Therapeutics aims to significantly improve the efficiency and effectiveness of the drug development process.
Strategic Partnerships and Funding
Genesis Therapeutics has garnered the support of several prominent investors, reflecting the confidence the industry has in its innovative approaches. Key investors include Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVIDIA Ventures, and BlackRock. The company has also announced a notable AI discovery deal with Eli Lilly, which consists of $20M in upfront cash and a potential total value of $670M.
Eli Lilly AI Discovery Deal
Genesis Therapeutics has recently announced a significant AI discovery deal with pharmaceutical giant Eli Lilly. The agreement includes an upfront payment of $20M and holds a potential total value of $670M. This deal is focused on leveraging Genesis Therapeutics' AI-driven technologies to discover and develop new drug candidates, signifying a major step forward in the collaboration between AI and traditional pharmaceutical research.